Cargando…

Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study

PURPOSE: Primary mediastinal B‐cell lymphoma (PMBCL) is a rare subtype of diffuse large B‐cell lymphoma (DLBCL). Despite its aggressive course, PMBCL is considered curable. While in recent years dose‐adjusted (DA) EPOCH‐R (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgenstern, Yael, Aumann, Shlomzion, Goldschmidt, Neta, Gatt, Moshe E., Nachmias, Boaz, Horowitz, Netanel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683525/ https://www.ncbi.nlm.nih.gov/pubmed/34816617 http://dx.doi.org/10.1002/cam4.4387

Ejemplares similares

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

Real world experience of R‐CHOP with or without consolidative radiotherapy vs DA‐EPOCH‐R in the first‐line treatment of primary mediastinal B‐cell lymphoma
por: Chan, Esther Hian Li, et al.
Publicado: (2019)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution
por: Liang, Yuanzheng, et al.
Publicado: (2023)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
por: Aumann, Shlomzion, et al.
Publicado: (2021)

Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients
por: Sabbah, Rozan, et al.
Publicado: (2023)

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Radiation therapy in primary mediastinal large B‐cell lymphoma treated with DA‐R‐EPOCH
por: Gentille, Cesar, et al.
Publicado: (2020)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
por: Aumann, Shlomzion, et al.
Publicado: (2022)

Primary Mediastinal B-cell Lymphoma Presenting as Chest Pain in a Young Woman and Treated with EPOCH-R
por: Weidenbaum, Chloe, et al.
Publicado: (2022)

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution
por: Huang, Jia-Jia, et al.
Publicado: (2016)

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
por: Devi, Kanta, et al.
Publicado: (2021)

P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES
por: Vassilakopoulos, T., et al.
Publicado: (2022)

R-CHOP方案和R-DA-EPOCH方案一线治疗non-GCB型弥漫大B细胞淋巴瘤回顾性研究
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2023)

Complete Response to R-EPOCH in Primary Cardiac Lymphoma
por: Anand, Kartik, et al.
Publicado: (2019)

Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

R-CHOP-Associated Graves' Hyperthyroidism
por: Mora, Natalie, et al.
Publicado: (2019)

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
por: Held, Gerhard, et al.
Publicado: (2023)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
por: Lebel, Eyal, et al.
Publicado: (2023)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS
por: Vassilakopoulos, T., et al.
Publicado: (2022)

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study
por: Lebel, Eyal, et al.
Publicado: (2023)

The lymphoma microenvironment comes of age in the R-CHOP era?
por: Cooper, Alan, et al.
Publicado: (2023)

Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy
por: Okada, Naoto, et al.
Publicado: (2014)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

R-CHOP versus CHOP in HIV-associated lymphoma: a meta-analysis of prospective studies
por: Echenique, Ignacio, et al.
Publicado: (2012)

Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2021)

Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting
por: Okello, Clement D., et al.
Publicado: (2020)

Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R: A case report
por: Porpaczy, Edit, et al.
Publicado: (2016)

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
por: Lakhotia, Rahul, et al.
Publicado: (2023)

R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study
por: Kagami, Yoshitoyo, et al.
Publicado: (2020)

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
por: Melani, Christopher, et al.
Publicado: (2018)

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_orcmmubnbh681v7v3mheqs3t85